LSV Asset Management Purchases 579,377 Shares of Pfizer Inc. $PFE

LSV Asset Management increased its position in shares of Pfizer Inc. (NYSE:PFE) by 3.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 17,502,714 shares of the biopharmaceutical company’s stock after buying an additional 579,377 shares during the period. Pfizer makes up 1.0% of LSV Asset Management’s holdings, making the stock its 16th biggest holding. LSV Asset Management’s holdings in Pfizer were worth $435,818,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the company. Advisory Alpha LLC raised its stake in Pfizer by 5.3% during the fourth quarter. Advisory Alpha LLC now owns 41,790 shares of the biopharmaceutical company’s stock worth $1,041,000 after buying an additional 2,122 shares during the last quarter. SGL Investment Advisors Inc. bought a new position in Pfizer during the fourth quarter worth $385,000. Keudell Morrison Wealth Management bought a new position in Pfizer during the fourth quarter worth $489,000. Axxcess Wealth Management LLC raised its stake in Pfizer by 100.9% during the fourth quarter. Axxcess Wealth Management LLC now owns 408,819 shares of the biopharmaceutical company’s stock worth $10,180,000 after buying an additional 205,305 shares during the last quarter. Finally, Van Hulzen Asset Management LLC raised its stake in Pfizer by 46.3% during the fourth quarter. Van Hulzen Asset Management LLC now owns 35,991 shares of the biopharmaceutical company’s stock worth $896,000 after buying an additional 11,382 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on PFE. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, February 4th. Barclays began coverage on shares of Pfizer in a research note on Thursday, February 19th. They set an “underweight” rating and a $25.00 target price on the stock. Morgan Stanley increased their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. UBS Group increased their target price on shares of Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research note on Monday, April 13th. Finally, HSBC increased their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.61.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s Phase 3 Lyme vaccine trial is nearing completion, which could be an important step toward a new potential growth driver if the data are supportive. Pfizer’s Phase 3 Lyme Vaccine Trial Nears the Finish Line: What Investors Should Know
• Positive Sentiment: Pfizer is also advancing a broader pneumococcal vaccine strategy, including positive Phase 2 infant data and a new Phase 3 pediatric program, which supports the company’s long-term vaccine franchise. Pfizer’s Broader Pneumococcal Vaccine Push Might Change The Case For Investing In Pfizer (PFE)
• Positive Sentiment: Pfizer’s HYMPAVZI expansion in Europe and the new Rigel licensing arrangement for VEPPANU add to the company’s revenue opportunities beyond its legacy products. Here’s Why Pfizer (PFE) Is One of the Most Undervalued US Stocks Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story
• Neutral Sentiment: Pfizer is testing new tablet formulations for tafamidis and migraine treatments in early-stage bioequivalence studies, which are routine development updates but do not yet imply a major commercial impact. Pfizer Tests New Tafamidis Tablet Forms in Phase 1 Bioequivalence Study Pfizer Advances New Migraine Tablet Formulation With Phase 1 Bioequivalence Study
• Neutral Sentiment: Pfizer also disclosed an observational biosimilar study in Japan, another incremental pipeline item that appears more informational than immediately market-moving. Pfizer’s Bevacizumab Biosimilar Study in Japan: What Investors Should Watch
• Negative Sentiment: Pfizer ended an early Phase 1 KRAS cancer trial, which may be viewed as a setback in one of the company’s closely watched oncology programs. Pfizer Terminates Early KRAS Cancer Trial: What It Means for PFE Investors
• Negative Sentiment: Some analyst coverage continues to flag patent risk and competitive pressure, which may limit enthusiasm despite the recent pipeline progress. J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?

Pfizer Stock Down 0.1%

Shares of NYSE PFE opened at $25.92 on Friday. The firm has a market cap of $147.72 billion, a PE ratio of 19.79 and a beta of 0.35. Pfizer Inc. has a 12-month low of $22.88 and a 12-month high of $28.75. The company’s fifty day simple moving average is $26.86 and its 200 day simple moving average is $26.23. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same period last year, the firm earned $0.92 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.